Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 23.67 0.81% 0.19
DCPH closed up 0.81 percent on Friday, May 24, 2019, on approximately normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Flat
See historical DCPH trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.81%
Fell Below 50 DMA Bearish 0.81%
MACD Bearish Centerline Cross Bearish 0.81%
Bollinger Band Squeeze Range Contraction 0.81%
BB Squeeze Started Range Contraction 0.81%
BB Squeeze + Upper Band Touch Range Contraction 0.81%
Upper Bollinger Band Touch Strength 0.81%

Older signals for DCPH ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Medicine Biopharmaceutical Cancer Drugs Immune System Cancer Treatments Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Glioblastoma Multiforme Protein Kinase Inhibitor Mastocytosis Treatment For Cancer Systemic Mastocytosis
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.61
52 Week Low 18.55
Average Volume 163,060
200-Day Moving Average 27.1079
50-Day Moving Average 23.7334
20-Day Moving Average 23.5115
10-Day Moving Average 23.649
Average True Range 1.3252
ADX 16.7
+DI 16.1658
-DI 17.3765
Chandelier Exit (Long, 3 ATRs ) 21.1544
Chandelier Exit (Short, 3 ATRs ) 25.9656
Upper Bollinger Band 24.7973
Lower Bollinger Band 22.2257
Percent B (%b) 0.56
BandWidth 10.937626
MACD Line -0.0079
MACD Signal Line -0.0879
MACD Histogram 0.08
Fundamentals Value
Market Cap 755.66 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.48
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.47
Resistance 3 (R3) 25.50 24.93 25.17
Resistance 2 (R2) 24.93 24.47 24.92 25.07
Resistance 1 (R1) 24.30 24.19 24.62 24.27 24.97
Pivot Point 23.73 23.73 23.89 23.72 23.73
Support 1 (S1) 23.10 23.27 23.42 23.07 22.37
Support 2 (S2) 22.53 22.99 22.52 22.27
Support 3 (S3) 21.90 22.53 22.17
Support 4 (S4) 21.87